References
<A NAME="RD13702ST-1A">1a</A> Vancomycin:
Glycopeptide Antiobiotics
Nagarajan R.
Marcel Dekker;
New York:
1994.
<A NAME="RD13702ST-1B">1b</A> Cyclosporine A:
Wenger RM.
Prog. Chem. Org. Nat. Prod.
1986,
50:
123
<A NAME="RD13702ST-1C">1c</A> Polyoxins :
Isono K.
Suzuki S.
Heterocycles
1979,
13:
333
<A NAME="RD13702ST-1D">1d</A> Cyclomarins:
Renner MK.
Shen Y.-C.
Cheng X.-C.
Jensen PR.
Frankmoelle W.
Kauffman CA.
Fenical WE.
Lobkovsky E.
Clardy J.
J. Am. Chem. Soc.
1999,
121:
11273
For selected recent examples, see:
<A NAME="RD13702ST-2A">2a</A>
MacMillan JB.
Molinski TF.
Org.
Lett.
2002,
4:
1883
<A NAME="RD13702ST-2B">2b</A>
Loncaric C.
Wulff WD.
Org. Lett.
2001,
3:
3675
<A NAME="RD13702ST-2C">2c</A>
DeMong DE.
Williams RM.
Tetrahedron
Lett.
2001,
42:
183
<A NAME="RD13702ST-2D">2d</A>
Kim IH.
Kirk KL.
Tetrahedron Lett.
2001,
42:
8401
For example:
<A NAME="RD13702ST-3A">3a</A>
Horikawa M.
Busch-Petersen J.
Corey EJ.
Tetrahedron
Lett.
1999,
40:
3843
<A NAME="RD13702ST-3B">3b</A>
Kobayashi S.
Ishitani H.
Ueno M.
J.
Am. Chem. Soc.
1998,
120:
431
<A NAME="RD13702ST-4">4</A> For the use of isocyanoacetates in
direct catalytic aldol additions, see:
Ito Y.
Sawamura M.
Hayashi T.
J.
Am. Chem. Soc.
1986,
108:
6405
<A NAME="RD13702ST-5A">5a</A>
Evans DA.
Weber AE.
J.
Am. Chem. Soc.
1986,
108:
6757
<A NAME="RD13702ST-5B">5b</A>
Volkmann RA.
Davis JT.
Meltz CN.
J. Am. Chem. Soc.
1983,
105:
5946
<A NAME="RD13702ST-5C">5c</A>
Hoppe D.
Follmann R.
Chem. Ber.
1976,
109:
3047
For examples, see:
<A NAME="RD13702ST-6A">6a</A>
Ji J.
Barnes DM.
Zhang J.
King SA.
Wittenberger SJ.
Morton HE.
J.
Am. Chem. Soc.
1999,
121:
10215
<A NAME="RD13702ST-6B">6b</A>
Frantz DE.
Fassler R.
Carreira EM.
J. Am. Chem. Soc.
1999,
121:
11245 ; ref. 5a
<A NAME="RD13702ST-7">7</A> For an example of alcohol additives
aiding catalyst turnover, see:
Evans DA.
Scheidt KA.
Johnston JN.
Willis MC.
J.
Am. Chem. Soc.
2001,
123:
4480
For impressive recent examples of
TMSCl being employed as an additive in diastereoselective MgCl2 catalysed
aldol reactions, see:
<A NAME="RD13702ST-8A">8a</A>
Evans DA.
Tedrow JS.
Shaw JT.
Downey CW.
J.
Am. Chem. Soc.
2002,
124:
392
<A NAME="RD13702ST-8B">8b</A>
Evans DA.
Downey CW.
Shaw JT.
Tedrow JS.
Org.
Lett.
2002,
4:
1127
<A NAME="RD13702ST-9">9</A>
A reaction using only Et3N
(no metal salt or bipyridine) provided an 8% yield of the
aldol adducts after 48 h at r.t. Reactions excluding Et3N
provided no product.
<A NAME="RD13702ST-10">10</A>
For a recent example of Lewis acid
catalysed reaction in which the addition of an external ligand was
needed to achieve reaction, see ref.
[6a]
<A NAME="RD13702ST-11">11</A>
The Preparation
of 3 Serves as a Typical Procedure: Mg(ClO4)2 (31
mg, 0.138 mmol) and bipyridine (22 mg, 0.138 mmol) were stirred
for 10 min in dry THF (5.5 mL) under nitrogen at r.t. Triethylamine
(39 µL, 0.276 mmol) was then added and the mixture was
cooled at 0 °C. After 10 min ethyl isothiocyanatoacetate
(170 µL, 1.38 mmol) and benzaldehyde (150 µL,
1.52 mmol) were added. After 20 h at 0 °C, the
reaction was quenched with a sat. aq ammonium chloride solution
(5 mL). The organic layer was separated and the aq layer was extracted
with dichloromethane (3 × 10 mL). The
organic portions were washed with a sat. aq copper sulphate solution
(5 mL) and with brine (5 mL), dried (MgSO4) and concentrated
under reduced pressure. The residue was purified by flash chromatography
(SiO2, EtOAc-DCM, 2:98) to give a mixture of
the syn- and anti-oxazolidinethiones, 3 (290 mg, 84%, syn:anti = 65:35),
as a viscous oil. Analytical samples were prepared by recrystallisation
from dichloromethane/petroleum spirit 40-60 °C.
<A NAME="RD13702ST-12">12</A>
Small amounts of a by-product originating
from the addition of a second equivalent of ester 1 to
the initially formed aldol adduct could be isolated in several experiments
when conducted at r.t.
<A NAME="RD13702ST-13">13</A>
All new compounds were fully characterised.
Selected data for novel compounds:
(4
R
*,5
R
*)
-
Ethyl 5-(4-nitrophenyl)-2-thioxo-oxazolidine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 8.28-8.24 (2
H, m), 7.71 (1 H, s), 7.57-7.54 (2 H, m), 6.19 (1 H, d, J = 9.8 Hz), 5.00 (1 H, d, J = 9.8 Hz), 3.87 (1 H, app.
dq, J = 10.8 and 7.2 Hz), 3.72
(1 H, app. dq, J = 10.8 and
7.2 Hz), 0.89 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3): δ = 189.5,
166.6, 148.8, 140.2, 128.1, 124.0, 83.9, 62.9, 62.8, 14.1.
(4
R
*,5
R
*)
-
Ethyl 5-(4-cyanophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.72-7.46
(4 H, m), 7.36 (1 H, s), 6.12 (1 H, d, J = 9.8
Hz), 4.94 (1 H, d, J = 9.8 Hz),
3.85 (1 H, app. dq, J = 10.7
and 7.2 Hz), 3.72 (1 H, app. dq, J = 10.7
and 7.2 Hz), 0.88 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3-CD3OD,
66:33): δ = 189.6, 167.0, 138.9, 132.2, 127.5,
118.0, 113.1, 83.7, 63.0, 62.1, 13.6.
(4
S
*,5
R
*)-Ethyl
5-(4-cyanophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 8.09 (1 H,
s), 7.75-7.54 (4 H, m), 6.03 (1 H, d, J = 6.2
Hz), 4.44 (1 H, d, J = 6.2 Hz),
4.41-4.29 (2 H, m), 1.37 (3 H, app. t,
J = 7.2 Hz). 13C
NMR (100 MHz, CDCl3): δ = 188.2, 167.2, 141.6,
132.8, 126.1, 117.9, 113.4, 84.0, 64.4, 63.4, 14.2.
(4
R
*,5
R
*)
-
Ethyl 5-(4-bromophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.58 (1 H,
s), 7.53-7.50 (2 H, m), 7.23-7.18 (2 H, m), 6.04
(1 H, d, J = 9.8 Hz), 4.90 (1
H, d, J = 9.8 Hz), 3.85 (1 H,
app. dq, J = 10.7 and 7.2 Hz),
3.74 (1 H, app. dq, J = 10.7
and 7.2 Hz), 0.89 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3): δ = 189.8,
166.9, 132.4, 132.0, 128.6, 124.2, 84.7, 62.9, 62.7, 14.0.
(4
S
*,5
R
*)-Ethyl 5-(4-bromophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.95 (1 H,
s), 7.58-7.55 (2 H, m), 7.31-7.26 (2 H, m), 5.93
(1 H, d, J = 6.2 Hz), 4.43 (1
H, d, J = 6.2 Hz), 4.39-4.27
(2 H, m), 1.35 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3): δ = 188.4,
167.5, 135.6, 132.2, 127.2, 123.6, 84.8, 64.5, 63.2, 14.2.
(4
R
*,5
R
*)
-
Ethyl 5-(3-bromophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.54-7.47
(3 H, m), 7.29-7.27 (2 H, m), 6.04 (1 H, d, J = 9.8 Hz), 4.91 (1 H, d, J = 9.8 Hz), 3.86 (1 H, app.
dq, J = 10.8 and 7.2 Hz), 3.76
(1 H, app. dq, J = 10.8 and
7.2 Hz), 0.90 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3): δ = 189.8, 166.8,
135.5, 133.0, 130.5, 130.0, 125.5, 122.8, 84.4, 62.9, 62.8, 14.0.
(4
S
*,5
R
*)-Ethyl 5-(3-bromophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.78 (1 H,
s), 7.57-7.53 (2 H, m), 7.37-7.29 (2 H, m), 5.94
(1 H, d, J = 6.2 Hz), 4.45 (1
H, d, J = 6.2 Hz), 4.41-4.28
(2 H, m), 1.36 (3 H, app. t, J = 7.0
Hz). 13C NMR (100 MHz, CDCl3): δ = 188.7,
167.7, 139.1, 132.9, 131.0, 128.8, 124.4, 123.4, 84.8, 64.8, 63.6,
14.6.
(4
R
*,5
R
*)
-
Ethyl 5-(2-bromophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.58-7.23
(5 H, m), 6.41 (1 H, d, J = 9.0
Hz), 5.00 (1 H, d,
J = 9.0
Hz), 3.80 (1 H, app. dq, J = 10.7
and 7.2 Hz), 3.66
(1 H, app. dq, J = 10.7and
7.2 Hz), 0.82 (3 H, app. t, J = 7.2 Hz). 13C
NMR (100 MHz, CDCl3): δ = 189.8, 166.9,
132.6, 132.3, 130.7, 127.8, 127.7, 122.1, 84.5, 62.2, 61.2, 13.6.
(4
S
*,5
R
*)-Ethyl 5-(2-bromophenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 8.00 (1 H,
s), 7.62-7.25 (4 H, m), 6.34 (1 H, d, J = 4.7
Hz), 4.46 (1 H, d, J = 4.7 Hz),
4.37-4.27 (2 H, m), 1.35 (3 H, app. t,
J = 7.3 Hz). 13C
NMR (100 MHz, CDCl3): δ = 188.8, 167.4, 135.5,
133.3, 130.8, 128.1, 127.6, 120.9, 84.6, 64.0, 63.0, 14.2.
(4
R
*,5
R
*)
-
Ethyl 5-(4-methoxyphenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.51 (1 H,
s), 7.25-7.21 (2 H, m), 6.90-6.86 (2 H, m), 6.04
(1 H, d, J = 9.8 Hz), 4.86 (1
H, d, J = 9.8 Hz), 3.84 (1 H,
app. dq, J = 10.7 and 7.2 Hz),
3.80 (3 H, s), 3.73 (1 H, app. dq, J = 10.7
and 7.2 Hz), 0.88 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3): δ = 189.9,
167.1, 160.7, 128.3, 125.4, 114.1, 85.5, 63.0, 62.5, 55.7, 14.0.
(4
S
*,5
R
*)-Ethyl 5-(4-methoxyphenyl)-2-thioxo-oxazoli-dine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.71 (1 H,
s), 7.34-7.32 (2 H, m), 6.96-6.92 (2 H, m), 5.90
(1 H, d, J = 6.2 Hz), 4.47 (1
H, d, J = 6.2 Hz), 4.37-4.25
(2 H, m), 3.82 (1 H, s), 1.34 (3 H, app. t, J = 7.0
Hz). 13C NMR (100 MHz, CDCl3): δ = 188.6,
167.7, 160.4, 128.5, 127.3, 114.4, 85.8, 64.4, 62.9, 55.4, 14.2.
(4
R
*,5
R
*)
-
Ethyl 5-(2-naphthyl)-2-thioxo-oxazolidine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.86-7.83
(4
H, m), 7.55-7.50 (3 H, m), 7.39-7.36 (1 H, m),
6.26 (1 H, d, J = 9.8 Hz), 4.97
(1 H, d, J = 9.8 Hz), 3.64 (1
H, app. dq, J = 10.4 and 7.2
Hz), 3.48 (1 H, app. dq, J = 10.4
and 7.2 Hz), 0.55 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3): δ = 189.7,
166.7, 133.5, 132.5, 130.3, 128.4, 128.1, 127.6, 126.9, 126.7, 126.4,
123.3, 85.4, 62.8, 62.2, 13.4. (4
S
*,5
R
*)-Ethyl
5-(2-naphthyl)-2-thioxo-oxazolidine-4-carboxylate. 1H
NMR (400 MHz, CDCl3): δ = 7.92-7.85
(5
H, m), 7.55-7.53 (2 H, m), 7.48-7.46 (1 H, m),
6.14 (1 H, d, J = 6.2 Hz), 4.56
(1 H, d, J = 6.2 Hz), 4.42-4.29
(2 H, m), 1.38 (3 H, app. t, J = 7.2
Hz). 13C NMR (100 MHz, CDCl3): δ = 189.1,
168.1, 134.1, 133.8, 133.1, 129.7, 128.5, 128.0, 127.3, 127.1, 125.6,
122.6, 86.1, 64.9, 63.4, 14.6.